CD30 in Systemic Mastocytosis

被引：19
作者：
van Anrooij, Bjorn [1 ]
Kluin, Philip M. [2 ]
Elberink, Joanne N. G. Oude [1 ]
Kluin-Nelemans, Johanna C. [3 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD, Dept Allergol, NL-9713 GZ Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, NL-9713 GZ Groningen, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, NL-9713 GZ Groningen, Netherlands
来源：
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA | 2014年 / 34卷 / 02期
关键词：
CD30; Soluble CD30; ligand; CD153; Systemic mastocytosis; LARGE-CELL LYMPHOMA; HODGKINS-DISEASE; SOLUBLE CD30; T-CELLS; B-CELLS; BRENTUXIMAB VEDOTIN; MYCOSIS-FUNGOIDES; LIGAND EXPRESSION; HUMAN EOSINOPHILS; SERUM-LEVEL;
D O I：
10.1016/j.iac.2014.01.006
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
CD30 is a transmembrane receptor, normally not expressed by mast cells, which regulates proliferation/apoptosis and antibody responses. Aberrant expression of CD30 by mastocytosis mast cells and interaction with its ligand CD30L (CD153) appears to play an important role in the pathogenesis and clinical presentation of systemic mastocytosis. This article highlights the expression profile and role of CD30 and CD3OL in physiologic and pathologic conditions, the applicability of CD30 as a marker for systemic mastocytosis, the consequences of mast cell-expressed CD30, and the possibility of future anti-CD30 based cytoreductive therapies.
引用
收藏
页码：341 / +
页数：16
相关论文
共 95 条
  • [1] Cloning and characterization of a cDNA for rat CD30 homolog and chromosomal assignment of the genomic gene
    Aizawa, S
    Satoh, H
    Horie, R
    Ito, K
    Choi, SH
    Takeuchi, H
    Watanabe, T
    [J]. GENE, 1996, 182 (1-2) : 155 - 162
  • [2] ANDREESEN R, 1989, AM J PATHOL, V134, P187
  • [3] Ansari MQ, 1996, AM J CLIN PATHOL, V105, P221
  • [4] Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma
    Ansell, Stephen M.
    Horwitz, Steven M.
    Engert, Andreas
    Khan, Khuda Dad
    Lin, Thomas
    Strair, Roger
    Keler, Tibor
    Graziano, Robert
    Blanset, Diann
    Yellin, Michael
    Fischkoff, Steven
    Assad, Albert
    Borchmann, Peter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) : 2764 - 2769
  • [5] Arredondo AR, 2011, LAB INVEST, V91, p285A
  • [6] A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies
    Bartlett, Nancy L.
    Younes, Anas
    Carabasi, Matthew H.
    Forero, Andres
    Rosenblatt, Joseph D.
    Leonard, John P.
    Bernstein, Steven H.
    Bociek, R. Gregory
    Lorenz, Jennie M.
    Hart, Bruce W.
    Barton, Jeremy
    [J]. BLOOD, 2008, 111 (04) : 1848 - 1854
  • [7] NK cells protect secondary lymphoid tissue from cytomegalovirus via a CD30-dependent mechanism
    Bekiaris, Vasileios
    Gaspal, Fabrina
    McConnell, Fiona M.
    Kim, Mi-Yeon
    Withers, David R.
    Sweet, Clive
    Anderson, Graham
    Lane, Peter J. L.
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2009, 39 (10) : 2800 - 2808
  • [8] Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases
    Benner, Marchina F.
    Jansen, Patty M.
    Vermeer, Maarten H.
    Willemze, Rein
    [J]. BLOOD, 2012, 119 (07) : 1643 - 1649
  • [9] Nuclear and cytoplasmic AID in extrafollicular and germinal center B cells
    Cattoretti, Giorgio
    Buettner, Maike
    Shaknovich, Rita
    Kremmer, Elisabeth
    Alobeid, Bachir
    Niedobitek, Gerald
    [J]. BLOOD, 2006, 107 (10) : 3967 - 3975
  • [10] Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells
    Cerutti, A
    Kim, EC
    Shah, S
    Schattner, EJ
    Zan, H
    Schaffer, A
    Casali, P
    [J]. NATURE IMMUNOLOGY, 2001, 2 (02) : 150 - 156
12345678910